Table 4 Clinical characteristics of patients with and without HBS following total parathyroidectomy

No. of patients

45

17

-

Male gender

8 (16.7%)

8 (47.1%)

0.019

Age (years)

54.5 ± 12.5

47.5 ± 10.2

0.043

Body weight (kg)

49.8 (44.9–61.6)

60.7 (50.4–71.2)

0.01

PD (%)

77.8

58.8

0.136

Duration of dialysis (years)

5.9 ± 2.3

6.0 ± 3.3

0.904

Kt/V (weekly)

2.26 ± 0.80

2.47 ± 1.21

0.439

 iPTH–peak (pmol/L)

164 (123–213)

189 (151–243)

0.144

 iPTH–immediately before operation (pmol/L)

154 (117–211)

183 (137–221)

0.237

 ALP–peak (IU/L)

250 (178–496)

415 (226–738)

0.051

 ALP–immediately before operation (IU/L)

221 (149–397)

415 (221–727)

0.008

 Calcium^a (mmol/L)

2.62 ± 0.18

2.44 ± 0.23

0.001

 Phosphate (mmol/L)

2.26 ± 0.58

2.34 ± 0.81

0.637

 Albumin (g/L)

30 ± 5

32 ± 5

0.220

 Haemoglobin (g/dL)

10.0 ± 1.4

9.5 ± 1.7

0.242

 Use of phosphate binders

21 (46.7%)

10 (58.8%)

0.393

  Calcium carbonate

15 (33.3%)

6 (35.3%)

0.884

  Aluminium hydroxide

1 (2.2%)

3 (17.6%)

0.059

  Lanthanum

2 (4.4%)

1 (5.9%)

1.000

  Sevelamer

4 (8.9%)

0

0.568

 Use of active vitamin D

16 (35.6%)

7 (41.2%)

0.683

  Calcitriol

1 (2.2%)

2 (11.8%)

0.180

  Alfacalcidol

9 (20%)

3 (17.6%)

1.000

  Paricalcitol

6 (13.3%)

2 (11.8%)

1.000

 Use of cinacalcet

8 (17.8%)

6 (35.3%)

0.141

4 glands resected

35 (77.8%)

13 (76.5%)

0.913

Weight of resected parathyroid tissue (g)

2.42 ± 1.63

2.93 ± 1.32

0.254

Parathyroid hyperplasia

43 (95.6%)

16 (94.1%)

1.000

iPTH at postoperative week 1 (pmol/L)

2.1 (0.5–6.6)

0.7 (0.4–3.9)

0.174